| Demographics and other baseline characteristics | |||
|---|---|---|---|
| No. (annual incidence,%) | EU | Japan | Taiwan |
| Total [N = 13,133] | Total [N = 11,330] | Total [N = 983] | |
|
Age [years], n (%) < 65 [65, 74] [75, 84] ≥ 85 |
1995 (15.2) 4449 (33.9) 5313 (40.5) 1375 (10.5) |
1666 (14.7) 3710 (32.7) 4354 (38.4) 1600 (14.1) |
159 (16.2) 381 (38.8) 312 (31.7) 131 (13.3) |
|
Recalc. eGFR (CG formula) [ml/min/1.73m2], n (%) ≥ 80 (50; 79) [30; 49] [15; 29] < 15 |
4127 (36.1) 4914 (43.0) 2107 (18.4) 289 (2.5) 3 (0.0) |
2417 (21.9) 5072 (46.0) 2990 (27.1) 542 (4.9) 6 (0.1) |
156 (16.6) 439 (46.9) 244 (26.0) 97 (10.4) 1 (0.1) |
|
Edoxaban dose at baseline, n (%) 60 mg Recommended Non‐Recommended 30 mg Recommended Non‐recommended |
10,036 (76.4) 8916 (67.9) 1120 (8.5) 3097 (23.6) 1992 (15.2) 1105 (8.4) |
3123 (27.6) 2866 (25.3) 257 (2.3) 8207 (72.4) 6777 (59.8) 1430 (12.6) |
432 (43.9) 315 (32.0) 117 (11.9) 551 (56.1) 373 (37.9) 178 (18.1) |
| Comparison with 1‐year outcome for EU, Japan and Taiwan | |||
|---|---|---|---|
|
No. (annual incidence,%) [95% CI] |
EU | Japan | Taiwan |
|
All‐cause mortality |
464 (3.62) [3.30; 3.96] |
277 (2.85) [2.54; 3.21] |
21 (2.19) [1.43; 3.36] |
|
Major bleeding |
135 (1.06) [0.89; 1.25] |
123 (1.27) [1.06; 1.52] |
13 (1.37) [0.79; 2.35] |
|
Intracranial hemorrhage (ICH) |
31 (0.24) [0.21; 0.65] |
38 (0.39) [0.29; 0.54] |
4 (0.42) [0.16; 1.11] |
|
Major GI bleeding |
53 (0.41) [0.32; 0.54] |
85 (0.88) [0.71; 1.09] |
5 (0.52) [0.22; 1.26] |
|
Any stroke |
92 (0.72) [0.59; 0.88] |
156 (1.61) [1.38; 1.89] |
13 (1.37) [0.79; 2.35] |
|
Stroke (ischemic) |
70 (0.55) [0.43; 0.69] |
121 (1.25) [1.05; 1.49] |
11 (1.16) [0.64; 2.09] |